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Abstract
Background: Whether tumor size and stage distribution are correlated remains controversial. The objective is to
assess the relationship between tumor size and disease stage distribution in non-small cell lung cancer (NSCLC).
Methods: We conducted a retrospective analysis of 917 cases of NSCLC that were resected in the Cancer Hospital
of Fudan University and Shanghai Sixth Hospital between January 2000 and February 2009. Tumor sizes were
grouped into five categories: ≤20 mm, 21 to 30 mm, 31 to 50 mm, 51 to 70 mm and ≥71 mm.
Results: Age and tumor size affected stage distribution: patients 60 years or older had a higher percentage of
N0M0 disease than patients younger than 60 years (61.67% vs. 44.85%, p < 0.01). The smaller the tumor, the more
likely the disease was N0M0 status (p < 0.05). For tumors ≤20 mm in diameter, the proportion of cases with N0M0
status was 70.79%, compared to 58.88% for 21 to 30 mm, 48.03% for 31 to 50 mm, 47.55% for 51 to 70 mm,
33.33% for ≥71 mm. The mean (± SD) tumor size of cases with N0M0 status was 37.17 ± 21.34 mm, compared to
45.75 ± 23.19 mm for cases with other status.
Conclusions: There is a statistically significant relationship between tumor size and distribution of disease stage of
primary NSCLC tumors: the smaller the tumor, the more likely the disease is N0M0 status.
Background
Lung cancer is the leading cause of cancer-related death
worldwide. A total of 497,908 new lung cancer cases
and 428,938 deaths from lung cancer are estimated to
have occurred in China in 2005 [1,2]. When diagnosis
and treatment are initiated early, lung cancer can be
cured. In the database of IASLC, the 5-year survival rate
of patients with pathologic and clinical stage IA non-
small cell lung cancer (NSCLC) is 73% and 50%, respec-
tively [3]. In contrast, the 5-year survival is only 13%
and 2% for patients with pathologic and clinical stage IV
disease, respectively [3]. Unfortunately, 75%~80%
patients with NSCLC are diagnosed with locally
advanced or advanced disease [4], resulting in a dismal
overall 5-year survival of 15.7% [5,6].
This state implies that to improve survival, efforts
should be made to detect NSCLC in earlier stages so
that curative surgery can be performed. Lung cancer
screening trials with conventional chest radiography
have failed to decrease lung cancer mortality [7-9].
However, the use of low-dose helical computed tomo-
graphy (CT) scans has refueled the impetus to detect
lung cancer at earlier stages. Compared to chest tomo-
graphy, CT scans can detect non-calcified nodules three
times more commonly and malignant nodules four
times more often [10-12]. Advocates of low-dose CT
screening believe that the smaller the lesion, the more
likely it is to be in an early stage. Tumor size is an
important characteristic of the T descriptors in the
seventh edition of the TNM classification for lung can-
cer [3], but whether tumor size correlates with stage dis-
tribution in NSCLC remains controversial. This study
was conducted to investigate the relationship between
tumor size and stage distribution in nearly 1000 Chinese
patients with resected NSCLC.
Methods
Between January 2000 and February 2009, 1083 patients
underwent surgery with curative intent for primary
NSCLC in the Cancer Hospital of Fudan University and
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the Shanghai Sixth Hospital. Inclusion criteria included
complete pathologic staging according to the TNM clas-
sification system of the UICC/AJCC and adequate docu-
mentation of tumor size, the type of lymphadenectomy
was systematic nodal dissection. Cases were retrospec-
tively analyzed, and all data were obtained from the
medical records, including gender, age, tumor location
(right or left side, upper or lower or middle lobe), histol-
ogy, tumor size, pathologic stage and the presence or
absence of lymph node or distant metastases. Routine
pre-operative examination included chest CT, abdominal
CT or ultrasonography or magnetic resonance imaging,
brain CT or magnetic resonance imaging, and bone
scanning. The final pathologic stage and the status of
lymph node or distant metastases were determined
based on pathology reports and clinical data. It was clas-
sified as N0 (no metastases), N1 (only ipsilateral peri-
bronchial, hilar, and/or intrapulmonary metastases), N2
(ipsilateral mediastinal and/or subcarinal metastases, no
contralateral), or N3 (contralateral mediastinal and/or
hilar, scalene, or supraclavicular metastases). Status of
distant metastases was classified as M0 (absent) or M1
(present). N0M0 status was defined as no metastases,
other status were defined as metastases. Tumor size was
defined by greatest diameter based on the pathology
report. Histology was divided into five categories
according to the 2004 World Health Organization clas-
sification of lung tumor: squamous cell carcinomas, ade-
nocarcinomas, adenosquamous cell carcinomas, large
cell carcinomas, and other histologic types of primary
NSCLC. Totally 158 patients were excluded. 148
patients were excluded because of the type of lymphade-
nectomy was not systematic nodal dissection. 10
patients were excluded because of the tumor size was
not clear from the pathology report. And 8 patients
were excluded because of neoadjuvant chemotherapy or
chemoradiotherapy. The remaining 917 cases were
received lobectomy or pneumonectomy.
According to the revision of the T descriptors in the
seventh edition of the TNM classification for lung can-
cer [13], we classify the 917 remaining cases of NSCLC
into the following five tumor size categories according
to the greatest diameter of tumor: ≤20 mm, 21~30 mm,
31~50 mm, 51~70 mm, and ≥71 mm. We focused prin-
cipally on the frequency of N0M0 status in these cate-
gories. Tumor size was used as a continuous variable.
Both parametric and nonparametric methods were used
to compare stage distributions relative to tumor size.
Univariate associations between disease stage and gen-
der, age, location of tumor, histology, and tumor size
were explored using c2 tests. The independent effect of
tumor size as categorical variables on disease stage was
analyzed using a logistic regression model. All the ana-
lyses were conducted using the statistical software
(SPSS15.0). All P values are two sided and considered
statistically significant when less than 0.05.
The study was conducted in accordance with the prin-
ciples of the Helsinki Declaration. And it was approved
by the Ethics Committee of Cancer Hospital of Fudan
University. Because this was a retrospective analysis,
patient’s consent was not required.
Results
A total of 917 patients (255 women, 27.81%, 662 men,
72.19%) with primary NSCLC met the inclusion criteria
and were analyzed. The mean (± standard deviation) age
was 60.15 ± 9.80 years, with a range from 20 to 83
years. Of the 917 cases, 339 cases (36.97%) were squa-
mous cell carcinomas, 448 cases (48.85%) adenocarcino-
mas, 57 cases (6.22%) adenosquamous cell carcinomas,
and 35 cases (3.82%) large cell carcinomas. The remain-
ing 38 cases (4.14%) were other histologic types of pri-
mary NSCLC. The tumor was left-sided in 418 cases
(45.58%), right-sided in 499 cases (54.42%). 522 cases
(56.92%) were upper-lobe, 63 cases (6.87%) were mid-
dle-lobe, 332 cases (36.21%) were lower-lobe. Among
the 917 cases, 178 (19.41%) were ≤20 mm in diameter,
214 (23.34%) cases were 20~30 mm, 304 (33.15%) cases
were 30~50 mm, 143 (15.59%) cases were 50~70 mm,
and 78 (8.51%) cases were ≥71 mm. The mean number
of N1 and N2 nodal stations removed are 2.01 and 4.00,
respectively. And the mean number of lymph node
removed is 18.18. 492 cases of non-small cell lung can-
cer were found to be N0M0 status. There were 23 cases
of stage IV disease. Among these, 4 cases were found to
be distant metastases before operation but the patients
and family members demanded surgery treatment. And
19 patients were found to have pleural nodules or
malignant pleural dissemination at operation. Three
cases of NSCLC were found to be N3 at operation.
Univariate analysis revealed that there were no asso-
ciations between sex, location of lung cancer, pathology
and stage distribution, while age and tumor size affected
stage distribution significantly. Patients 60 years or older
had higher percentages of N0M0 than the ones younger
than 60 years (61.67% vs. 44.85%, p < 0.001). Univariate
analysis revealed that tumor size affected stage distribu-
tion: the smaller the tumor, the more likely the disease
was N0M0. The proportion of cases with no metastasis
(N0M0) was 53.65% overall. For tumors ≤20 mm in dia-
meter, the proportion of cases with N0M0 was 70.79%
(95% confidence interval (CI), 64.11%~77.47%), com-
pared to 58.88% (95% CI, 52.29%~65.47%) for 21 to 30
mm, 48.03% (95% CI, 42.41%~53.64%) for 31 to 50 mm,
47.55% (95% CI, 39.15%~55.95%) for 51 to 70 mm,
33.33% (95% CI, 22.87%~43.79%) for ≥71 mm (Table 1).
The proportions of cases with N0M0 were significantly
different between all the successive categories (p < 0.05),
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except between tumors 31 to 50 mm and 51 to 70 mm
(p = 1.00). The proportions of cases with N0M0 were
statistically significantly different among all the non-
consecutive categories according to tumor size (p <
0.05). Tumor size did affect the distribution of stage in
the multivariate analysis with the following variables
entered to the multivariate analysis: gender, age, location
of tumor, histology, categories of tumor size.
The mean (± SD) tumor size of cases with N0M0 sta-
tus was 37.17 ± 21.34 mm, compared to 45.75 ± 23.19
mm for cases with other status. The tumor size of cases
with N0M0 disease was significantly smaller than all the
other cases (p < 0.01).
Discussion
The proportion of patients dying from lung cancer in
China rose 30.4% from 2000 to 2005 [1,2]. The inci-
dence rate continues to increase due to the high preva-
lence of smoking and China’s large population. Efforts
need to be made to detect lung cancer earlier, so
patients can live longer.
Proponents of CT screening for lung cancer believe
that highly sensitive CT scans may reduce mortality
from lung cancer. CT scans reportedly can detect lung
cancers with smaller lesions, leading to a significant
stage shift from advanced late stage disease to early,
more curable stages. According to the new lung cancer
staging system, tumor size is an important characteristic
of the T descriptors [3]. While more and more studies
support that tumor size is an important survival factor
in NSCLC [14-17], the association between tumor size
and stage distribution is still controversial.
The current study was conducted to analyze the rela-
tionship between clinicopathologic factors and disease
stage distribution. This study suggests that patients 60
year or older have higher percentage of N0M0 disease
than those younger than 60 year (61.67% vs. 44.85%, p <
0.001). Several factors may explain this finding. First,
higher proportion of older peoples seek and receive a
health examination, as they pay more attention to their
physical status. Consistent with this, many patients were
found to have incidental NSCLC when under evaluation
for other diseases. Second, younger patients tend to
have more aggressive NSCLC [18]. The third reason for
this is elderly patients are less likely than young ones to
be offered surgical treatment if the preoperative work-
up showed a more advanced tumor stage. This observa-
tion indicates that we cannot ignore lung cancer screen-
ing in younger people.
Studies on the effect of tumor size on disease stage
have conflicting results [19-22]. Although recent studies
of CT screening found relatively high percentages of
stage I NSCLC (70%~87%) [23-25], Swensen found no
statistically significant stage shift. He explained that the
high percentage of detected stage I lung cancers may be
due to a larger number of indolent cancers being
detected [26]. To test the presumption that smaller
lesions represent earlier stage diseases, Heyneman and
his colleagues conducted an analysis including 620 cases
who presented with pathologically proven primary
NSCLC measuring ≤3 cm [19]. They found no statisti-
cally significant differences in distribution of disease
stage according to tumor size categories. They asserted
that CT screening may not result in a shift from
advanced stage to earlier stage distribution. However,
cases from the study cohort were collected over a 20
year period and included only 25 cases with tumor sizes
<1 cm, while the percentage of stage I cases was very
high for all categories of tumor sizes. These factors may
lower the power to detect a relationship between tumor
size and disease stage. Henschke and colleagues demon-
strated an association between tumor size and stage dis-
tribution in either symptomatic or asymptomatic
patients [20,21]. One study utilizing the Surveillance,
Epidemiology, and End Results database including 84152
cases primary NSCLC revealed that tumor size did have
an effect on disease stage distribution: the smaller the
tumor, the more likely the disease was stage I [20]. In
another study performed by the I-ELCAP investigators,
Henschke concluded that lymph node status had a
strong relationship to tumor diameter for NSCLC in
screen-diagnosed lung cancers: the percentage of N0M0
cases was higher in patients with smaller tumors [21].
Flieder and his colleagues demonstrated that NSCLC
measuring 21~30 mm was twice as likely to have nodal
metastases as carcinomas ≤20 mm [22].
Our study suggests that there is a relationship
between tumor size and disease stage of NSCLC: the
Table 1 Distribution of disease stage according to tumor size
Tumor size (mm)
Stage of disease ≤20 21~30 31~50 51~70 ≥71 Total
N0M0 126 126 146 68 26 491
N1M0 13 29 48 24 19 133
N2M0 32 52 103 49 29 266
N0-2M1/N3M0-1 7 7 7 2 4 27
Total (% of N0M0) 178(70.79) 214(58.88) 304(48.03) 143(47.55) 78(33.33) 917(53.65)
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percentage of N0M0 disease decreased with increasing
tumor diameter. The proportion of N0M0 disease was
70.79% (95% CI, 64.11%~77.47%) for tumors ≤ 20 mm,
compared to 58.88% (95% CI, 52.29%~65.47%) for 21 to
30 mm, 48.03% (95% CI, 42.41%~53.64%) for 30 to 50
mm, 47.55% (95% CI, 39.15%~55.95%) for 51 to 70 mm,
33.33% (95% CI, 22.87%~43.79%) for ≥71 mm. The gra-
dients in the successive percentages of N0M0 were sig-
nificantly different (p < 0.05), except between tumors 31
to 50 mm and 51 to 70 mm (p = 1.00) (Figure 1). The
percentage of N0M0 disease for category of ≤20 mm
was significantly higher than all the other categories (p
< 0.05), and the gradients in all the non-successive per-
centages of N0M0 disease were significantly different (p
< 0.05). The tumor size of cases with N0M0 was signifi-
cantly smaller than all the other cases (p < 0.01). Logis-
tic regression model determined the true effect of tumor
size on stage distribution.
The current study was different from previous studies
[19-21]. In previous studies, thoracic CTs had an accu-
racy of only 75%~80% in assessing mediastinal lymph
nodes in NSCLC patients [27]. Lymph node metastasis
was recognized even in clinical T1N0M0 lung cancers
smaller than 2 cm [28]. 39% cases showed a mismatch
between clinical diameter based on thoracic CT and
postsurgical diameter [28]. These factors may lower the
accuracy of the results of previous studies. The status of
stage and tumor diameter in cases from our study was
more accurate than in previous studies, which included
cases whose staging and size of lesions were determined
only based on clinical examinations. All cases in our
study cohort received surgical treatment, and postsurgi-
cal pathologic stage and tumor diameter were obtained
from pathology reports. However, as in previous studies,
our study has a selection bias by including symptomatic
and asymptomatic patients. As Henschke said, compared
with large tumors, smaller tumors are more likely to be
symptomatic due to their lymph node or distant metas-
tases. As smaller tumors are not likely to cause local
symptoms and would remain mostly undetected unless
they have disseminated, while large cancers are more
likely to be symptomatic due to local invasion or com-
pression. This may dilute the size/stage relationship
within our database relative to that in a screening data-
base. Our study cohort also included only those who
underwent an operation, which could be another source
of bias.
The percentage of N2 disease in the 5 categories of
our study is higher than the result reported in the
IASLC database [29], probably because of a sparse use
of invasive staging procedures or PET-CT examination
before operation, especially before 2004 in the Cancer
Hospital of Fudan University.
The median diameter of lesions missed by chest radio-
graphy was 16 mm [30,31], while the median diameter
of primary lung cancers detected by CT screening was
15 mm [10-12,24-26]. Sone and colleagues reported that
the miss rate of lung cancers ≤ 2 cm on chest radiogra-
phy was 79% [32]. The mean size of lung cancer lesions
detected by chest radiography was 3 cm [33]. In conclu-
sion, our study suggests that tumor size at diagnosis has
a definite effect on the stage distribution of NSCLC:
Figure 1 Proportions of disease stage according to tumor size. The percentage of N0M0 disease decreased with the increasing of tumor
diameter. The proportion of cases with N0M0 was 70.79% for tumor ≤ 20 mm, compared to 58.88% for 21 to 30 mm, 48.03% for 31 to 50 mm,
47.55% for 51 to 70 mm, 33.33% for ≥ 71 mm. The proportions of cases with N0M0 were significantly different between all the successive
categories (p < 0.05), except between tumors 31 to 50 mm and 51 to 70 mm (p = 1.00).
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smaller lesions represent earlier stage disease. CT
screening can detect smaller lesions that represent more
early stage lung cancer.
Conclusions
Tumor size has a definite effect on stage of NSCLC:
smaller lesions represent earlier stage disease.
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